Incidence, consequences and treatment of bone metastases in breast cancer patients—Experience from a single cancer centre

Kuchuk, Iryna; Hutton, Brian; Moretto, Patrícia; Ng, Terry L.; Addison, Christina L.; Clemons, Mark

doi:10.1016/j.jbo.2013.09.001

Cited by 97 publications

(97 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We also validated the results of survival analysis in another independent cohort from FUSCC. Some studies have evaluated the epidemiology and prognosis of breast cancer patients with bone metastases at the population level, but most of the patients in these studies presented bone metastases after a diagnosis of early‐stage breast cancer 2, 20, 29, 30, 31, 32, 33. However, limited data have been reported in the specific group of patients with bone metastases upon their initial diagnosis of breast cancer 34.…”

Section: Discussionmentioning

confidence: 99%

Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis

Gong

Zhang

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

IntroductionPopulation‐based data on the incidence and prognosis of bone metastases at diagnosis of breast cancer are currently limited. Hence, we conducted this study to analyze the incidence proportions and prognostic factors of patients with breast cancer and bone metastases at the time of cancer diagnosis.Materials and methodsPatients with primary invasive breast cancer and bone metastases at initial diagnosis between 2010 and 2014 were identified using the Surveillance, Epidemiology, and End Results (SEER) dataset and Fudan University Shanghai Cancer Center (FUSCC) cohort. Multivariable logistic regression was performed to identify predictors of the presence of bone metastases at diagnosis. Univariate and multivariate analyses were performed to determine the effects of each variable on survival.ResultsOf 229, 195 patients from SEER database included in the analysis, 8295 patients had bone metastases at initial diagnosis, reflecting 3.6% of the entire study population, and 65.1% of the subset with metastatic disease to any distant site. Patients with hormone receptor (HR)‐positive human epidermal growth factor receptor 2 (HER2)‐negative represented the highest incidence proportions among patients with metastatic disease (73.9%). Among entire cohort, multivariable logistic regression identified eight factors as predictors of the presence of bone metastases at diagnosis. Median OS for the patients with bone metastases in SEER and FUSCC cohorts was 30.0 and 68.2 months, respectively. Patients with HR‐positive HER2‐positive subtype had the longest median OS, and patients with triple‐negative subtype showed the shortest median OS. Multivariable Cox model in SEER cohort confirmed age, histology, grade, tumor subtype, extraosseous metastatic sites, history of primary surgery, insurance status, marital status, and income as independent prognostic factors for both OS and BCSS.ConclusionsThe findings of this study provide population‐based estimates of the incidence and prognosis for patients with bone metastases at initial diagnosis of breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis

Gong

Zhang

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…The incidence of bone metastases is reported to be 6-6.5% [10,11]. In sixty-nine percent of diagnosed bone metastases, the chest cage is one of the locations where metastases are found [12]. Since metastases have a much higher incidence, this is a more likely diagnosis.…”

Section: Zuidberg-van Dermentioning

confidence: 99%

A Rare Sternal Lesion on Magnetic Resonance Mammography Mimicking a Metastasis in a Patient With a History of Mamma Carcinoma: A Case Report

et al. 2017

View full text Add to dashboard Cite

A 48-year-old female patient was sent to the radiology department for her annual control magnetic resonance imaging (MRI) after mastectomy for breast cancer. The MRI showed a solitary lesion in the manubrium sterni with homogeneous enhancement. Computed tomography (CT) showed a sclerotic lesion. The lesion showed minimal activity on bone scintigraphy. A biopsy was performed and histology revealed a lesion consisting of brown fat. The lesion was diagnosed as an intraosseous hibernoma. This case report highlights the importance of histologic confirmation of a suspected metastasis, since rare lesions can mimic metastases on imaging.

show abstract

“…However, the demographic and medical characteristics of the general population often differ from patients enrolled in clinical trials. There are only few data on the use of BTAs in routine care, and existing data are often limited by retrospective collection [6,19,20].…”

Section: Introductionmentioning

confidence: 99%

Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer – Results from the prospective German Tumour Registry Breast Cancer cohort study

Schröder¹,

Fietz²,

Köhler

et al. 2017

European Journal of Cancer

View full text Add to dashboard Cite

A high proportion of patients with breast cancer develop bone metastases, yet data on routine treatment with bone-targeted agents (BTA) are rare. We report real-life outcome data of patients with breast cancer metastasised to the bone treated by office-based oncologists in Germany.The ongoing, prospective, multicentre, population-based cohort study Tumour Registry Breast Cancer (TMK) was started in 2007 in 140 centres across Germany. This interim analysis of 1094 patients with bone metastases revealed differences among the tumour subtypes: at start of first-line therapy, 36% of the patients with hormone receptor (HR)-positive and only 20% of the patients with HR-negative tumours presented with bone-only metastasis. The majority of patients with bone metastases (89%, n Z 976) received BTA therapy. In 2014e2015, 37% of the patients received the bisphosphonate zoledronic acid and 36% the antibody denosumab. Median duration of BTA therapy was 20 months (interquartile range 31.5 months), starting a median of 3 weeks after diagnosis of bone metastases, and ending a median of 7 weeks before death. The median overall survival (OS) also varied among the types of metastasis at start of first-line therapy ranging from 54 months (95% confidence interval [CI] 37.6e70.8), 38 months (95% CI 29.4e44.2) to 28 months (95% CI 24.2 e31.0) for patients with bone-only metastases, non-visceral with or without bone metastases and visceral with or without bone metastases respectively.We show that choice and duration of BTA therapies are in conformity with guidelines applicable in Germany. To our knowledge, this is the first presentation of data on incidence, metastatic pattern, treatment and survival of patients with bone metastases in routine practice.

show abstract

Incidence, consequences and treatment of bone metastases in breast cancer patients—Experience from a single cancer centre

Cited by 97 publications

References 35 publications

Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis

Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis

A Rare Sternal Lesion on Magnetic Resonance Mammography Mimicking a Metastasis in a Patient With a History of Mamma Carcinoma: A Case Report

Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer – Results from the prospective German Tumour Registry Breast Cancer cohort study

Contact Info

Product

Resources

About